Cancer
Sanofi signs deal on pre-clinical cancer drugs
June 4, 2010Research and Development Cancer, Sanofi
Sanofi-Aventis has signed a deal with US biotech company Ascenta to co-develop new oncology treatments aimed at restoring ‘apoptosis’ or …
ASCO cancer conference opens
June 4, 2010Research and Development ASCO, Cancer, lenalidomide, rituximab
One of the most important dates in the pharmaceutical industry’s calendar, the ASCO cancer conference begins today. The American Society …
Vaccine for brain cancer shows promise
June 3, 2010Research and Development Cancer, GBM, ImmunoCellular
Early stage trials of a new treatment for the brain cancer glioblastoma multiforme have shown promise. ICT-107 is being developed …
Asda cuts cancer drugs prices
May 24, 2010Sales and Marketing Asda, Cancer, market access, price cuts, pricing, supermarket
UK supermarket chain Asda has started selling privately prescribed cancer drugs on a not-for-profit basis. The vast majority of drugs …
Boehringer signs antibody myeloma R&D deal
May 10, 2010Research and Development Boehringer, Cancer, Micromet, myeloma
Boehringer Ingelheim and US biotech company Micromet are to research and develop a new BiTE antibody to treat multiple myeloma. …
Collaborative cancer drug project targets research efficiency
May 5, 2010Research and Development Animal testing, Animal tests, Cancer, biomarkers, clinical drug development
A new pharma-academia project being managed by the University of Dundee is setting its sights on improving the effectiveness of …
Roche’s Xeloda widens licence
April 1, 2010Sales and Marketing Cancer, Roche, Xeloda, colorectal cancer
Roche’s oral chemotherapy drug Xeloda has been approved in Europe in combination with intravenous oxaliplatin for the treatment of patients …
Cephalon to develop new class of cancer drug
March 19, 2010Research and Development CRT, Cancer, Cancer Research UK, Cephalon
Pennsylvania-based Cephalon has signed a deal with the discovery arm of charity Cancer Research UK to develop a new class …
Roche delivers updated pipeline
March 18, 2010Cancer, Roche
Roche says its pipeline can sustain its growth in oncology and increase its presence in personalised healthcare. Roche also plans …
Pfizer suffers late-stage cancer drug failures
March 12, 2010Research and Development Cancer, Pfizer, Sutent, figitumumab
Pfizer has suffered late-stage trial failures for Sutent and lung cancer candidate figitumumab. Kidney cancer drug Sutent (sunitinib) failed to …
Recentin disappoints in colorectal cancer
March 9, 2010Research and Development AZ, Cancer, Recentin, colorectal cancer
AstraZeneca’s developmental oncology drug Recentin has failed to meet its primary endpoint in a phase II/III study. The once-daily oral …
NHS funding boost for cancer diagnosis
March 8, 2010Cancer, NHS, disease awareness campaigns
The government is to put £8 million into finding new ways of improving early cancer diagnosis for one or more …
Stability data issue holds up Adventrx cancer drug
March 3, 2010Manufacturing and Production, Sales and Marketing Adventrx, Cancer, vinorelbine
US drugmaker Adventrx Pharmaceuticals has had the marketing application for its cancer drug ANX-530 (vinorelbine emulsion) rejected by the US …
Alimta recommended as maintenance therapy
March 1, 2010Sales and Marketing Alimta, Cancer, NSCLC, lilly
NICE has recommended Alimta as a maintenance treatment for people with locally advanced or metastatic non-small cell lung cancer. Patients …
Sanofi’s BSI-201 tipped for success in triple negative breast cancer
February 28, 2010Sales and Marketing Cancer, PARP, Sanofi, breast cancer
Sanofi-Aventis’s BSI-201 will garner sales of $1.7 billion in the triple negative breast cancer drug market in 2018, according to …
Latest content
Migraine annual economic and quality-of-life burden in UK
bit.bio expands human heart cell portfolio through myriamed partnership
Phoenix Labs acquires Kent Pharma
Astoriom acquires Sampled’s UK stability storage operations
